Galecto Inc is an early-stage orphan drug development company.
The company is focusing on novel therapeutics for fibrosis and inflammatory-related diseases, including the lung disease Idiopathic Pulmonary Fibrosis (IPF).
The lead program is in clinical development and addresses a novel therapeutic target for IPF called Galectin-3.
Galecto is listed on Nasdaq New York (ticker: GLTO).
For more information, please contact:
Phone: +45 4081 4889